Next Article in Journal
Validation of the Target Protein of Insecticidal Dihydroagarofuran Sesquiterpene Polyesters
Next Article in Special Issue
The Kunitz-Type Protein ShPI-1 Inhibits Serine Proteases and Voltage-Gated Potassium Channels
Previous Article in Journal
Shiga Toxins as Multi-Functional Proteins: Induction of Host Cellular Stress Responses, Role in Pathogenesis and Therapeutic Applications
Previous Article in Special Issue
Structure-Activity Relationship of Chlorotoxin-Like Peptides
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessArticle
Toxins 2016, 8(3), 78;

Analgesic Effects of GpTx-1, PF-04856264 and CNV1014802 in a Mouse Model of NaV1.7-Mediated Pain

Centre for Pain Research, Institute for Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia
School of Pharmacy, The University of Queensland, Woolloongabba, QLD 4102, Australia
Department of Physiology and Pathophysiology and Department of Anaesthesiology, Friedrich-Alexander University Erlangen-Nuremberg, 91054 Erlangen, Germany
Department of Biomedical Science, University of Sheffield, Sheffield S10 2TN, UK
Author to whom correspondence should be addressed.
Academic Editors: Rong Chen and Yingliang Wu
Received: 25 January 2016 / Revised: 8 March 2016 / Accepted: 10 March 2016 / Published: 17 March 2016
(This article belongs to the Special Issue Animal Toxins and Biological Ion Channels)
Full-Text   |   PDF [3214 KB, uploaded 17 March 2016]   |  


Loss-of-function mutations of NaV1.7 lead to congenital insensitivity to pain, a rare condition resulting in individuals who are otherwise normal except for the inability to sense pain, making pharmacological inhibition of NaV1.7 a promising therapeutic strategy for the treatment of pain. We characterized a novel mouse model of NaV1.7-mediated pain based on intraplantar injection of the scorpion toxin OD1, which is suitable for rapid in vivo profiling of NaV1.7 inhibitors. Intraplantar injection of OD1 caused spontaneous pain behaviors, which were reversed by co-injection with NaV1.7 inhibitors and significantly reduced in NaV1.7−/− mice. To validate the use of the model for profiling NaV1.7 inhibitors, we determined the NaV selectivity and tested the efficacy of the reported NaV1.7 inhibitors GpTx-1, PF-04856264 and CNV1014802 (raxatrigine). GpTx-1 selectively inhibited NaV1.7 and was effective when co-administered with OD1, but lacked efficacy when delivered systemically. PF-04856264 state-dependently and selectively inhibited NaV1.7 and significantly reduced OD1-induced spontaneous pain when delivered locally and systemically. CNV1014802 state-dependently, but non-selectively, inhibited NaV channels and was only effective in the OD1 model when delivered systemically. Our novel model of NaV1.7-mediated pain based on intraplantar injection of OD1 is thus suitable for the rapid in vivo characterization of the analgesic efficacy of NaV1.7 inhibitors. View Full-Text
Keywords: OD1; NaV1.7; PF-04856264; CNV1014802; raxatrigine; GpTx-1; pain OD1; NaV1.7; PF-04856264; CNV1014802; raxatrigine; GpTx-1; pain

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Deuis, J.R.; Wingerd, J.S.; Winter, Z.; Durek, T.; Dekan, Z.; Sousa, S.R.; Zimmermann, K.; Hoffmann, T.; Weidner, C.; Nassar, M.A.; Alewood, P.F.; Lewis, R.J.; Vetter, I. Analgesic Effects of GpTx-1, PF-04856264 and CNV1014802 in a Mouse Model of NaV1.7-Mediated Pain. Toxins 2016, 8, 78.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top